NYSE:NUVBPharmaceuticals
Nuvation Bio Data And Japan Rights Add Weight To Undervalued Story
Nuvation Bio (NYSE: NUVB) reported new long term follow up data for IBTROZI (taletrectinib) in advanced ROS1 positive non small cell lung cancer, showing durable responses and strong intracranial activity.
The company also expanded its global rights to safusidenib, now including Japan, supporting the launch of pivotal trials there.
These updates come alongside an ongoing focus on building out Nuvation Bio's oncology franchise.
Nuvation Bio enters this news cycle with shares at $5.11 and a...